Neuland Laboratories Shares Gain Over 8% After USFDA Approval for BMS Schizophrenia Drug – Equitypandit
September 27, 2024September 27, 2024 Shares of Neuland Laboratories Ltd. rallied over 8% to reach a day’s high of Rs 13,630.00 on 27th September, following the USFDA approval of Bristol Myers Squibb’s (BMS) new schizophrenia drug, Cobenfy, also known as KarXT. According to market experts, the company is likely…